Advertisement


Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

2024 ASCO Annual Meeting

Advertisement

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study that I'm presenting is a multicenter consortium study. It consists of 1,327 patients that we looked at both genomic data through the liquid biopsy Guardant360 and clinical data that we got manually from the electronic medical record system. We decided to use this large multi-consortium database to ask questions about targeted treatment use in Black versus White patients. So we found that Black and White patients had equal incidence of PIK3CA mutations. But despite this equal incidence, they had differences in targeted treatment use. Black patients ended up having significantly less targeted treatment use than White patients in this dataset. Specifically, this was for these PI3 kinase inhibitor use. When we looked at mTOR inhibitor use and CDK4/6 inhibitor use, which does not require a specific finding in ctDNA or liquid biopsy, we actually didn't find any differences. So the only targeted treatment use differences was when there was a specific targeted finding in the ctDNA profiling. The other thing we looked at after that was we looked at overall survival in this cohort. We'd previously reported overall survival in the overall 1,327 patients, and then we looked specifically at HR-positive HER2-negative metastatic breast cancer patients, and we looked at ER positive, PR negative HER2 negative, and ER positive, PR positive HER2 negative. The PR-negative patients did significantly worse in terms of overall survival and Black patients with ER positive, PR negative HER2 negative did significantly worse than White patients with the same profile. Finally, we looked at clinical trial enrollment, so we looked at whether the patients with this PIK3CA mutation with metastatic breast cancer were enrolled in clinical trials at the same rate between Black and White patients. So we found that Black patients were significantly less likely to be enrolled in a clinical trial than White patients.

Related Videos

Gastroesophageal Cancer

Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Advertisement

Advertisement




Advertisement